An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy (Q33851141)

29 July 2017

1 reference

title

An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy (English)

1 reference

29 July 2017

1 reference

Duque JL

1

1 reference

PubMed ID

10696251

29 July 2017

Loughlin KR

series ordinal

2

1 reference

29 July 2017

1 February 2000

1 reference

Urologic Clinics of North America

29 July 2017

1 reference

29 July 2017

27

1 reference

29 July 2017

125-35, x

1 reference

29 July 2017

1

1 reference

Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Wor

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Treatment of superficial bladder cancer with intravesical chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Adjuvant intravesical therapy for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Adjuvant Chemotherapy of Recurrent Superficial Transitional Cell Carcinoma: Results of a European Organization for Research on Treatment of Cancer Randomized Trial Comparing Intravesical Instillation of Thiotepa, Doxorubicin and Cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

4'-Epidoxorubicin versus Mitomycin C Intravesical Chemoprophylaxis of Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Adjuvant intravesical mitoxantrone after transurethral resection of primary superficial transitional cell carcinoma of the bladder. A prospective randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Thiotepa in the treatment of tumours of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resectio

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Adjuvant Intravesicular Pharmacotherapy for Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Absorption Studies on Intraluminal Thio-Tepa for Topical Cytostatic Treatment of Low-Stage Bladder Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

The 4th study of prophylactic intravesical chemotherapy with adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese Urological Cancer Research Group for Adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urologi

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Intravesical mitozantrone in recurrent superficial bladder cancer: a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

A Longitudinal Study of Patients with Superficial Bladder Carcinoma Successfully Treated with Weekly Intravesical Thio-TEPA

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary ca

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Natural history and treatment of low and high risk superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Thiotepa-induced myelosuppression: review of 670 bladder instillations.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisati

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970240-8

7 January 2021

10.1016/S0094-0143(05)70240-8

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10696251